Investigational drug · Phase 2
ALLO-647
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Relapsed or Refractory Large B Cell Lymphoma, Relapsed or Refractory Chronic Lymphocytic Leukemia, Relapsed or Refractory Small Lymphocytic Lymphoma.
Phase 2Last checked: Nov 19, 2026Latest source record: Mar 4, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
6
Any phase or sponsor naming "ALLO-647"
First trial start
2020
May 21, 2020
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "ALLO-647", any sponsor or status.
Conditions studied
As listed on its trial records.
- Relapsed or Refractory Large B Cell Lymphoma, Relapsed or Refractory Chronic Lymphocytic Leukemia, Relapsed or Refractory Small Lymphocytic Lymphoma
Approved drugs for the same conditions: Chronic lymphocytic leukemia · Hematology and blood cancers
Largest trials
Live from ClinicalTrials.gov: studies naming "ALLO-647" as an intervention, largest first.
- Safety and Efficacy of ALLO-501A Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell Lymphoma, Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (ALPHA2)Active, not recruiting
Allogene TherapeuticsIndustry
NCT04416984 · 160 participants (planned) · Start May 21, 2020 · Primary completion Feb 2029
Drug: ALLO-647; Fludarabine and 1 more · For: Relapsed or Refractory Large B Cell Lymphoma, Relapsed or Refractory Chronic Lymphocytic Leukemia, Relapsed or Refractory Small Lymphocytic Lymphoma
Sites: Gilbert, Arizona; Phoenix, Arizona; Duarte, California · 29 sites in all
- Safety and Efficacy of ALLO-316 in Subjects With Advanced or Metastatic Clear Cell Renal Cell CarcinomaActive, not recruiting
Allogene TherapeuticsIndustry
NCT04696731 · 120 participants (planned) · Start Feb 24, 2021 · Primary completion Jan 2030
Drug: ALLO-647; Fludarabine and 1 more · For: Advanced/Metastatic Clear Cell Renal Cell Carcinoma
Sites: Duarte, California; Los Angeles, California; San Francisco, California · 10 sites in all
Allogene TherapeuticsIndustry
NCT04093596 · 73 participants · Start Sep 23, 2019 · Primary completion Jan 27, 2025
Drug: ALLO-647; Fludarabine and 2 more · For: Relapsed/Refractory Multiple Myeloma
Sites: Gilbert, Arizona; Duarte, California; Palo Alto, California · 11 sites in all
Allogene TherapeuticsIndustry
NCT03939026 · 50 participants · Start May 1, 2019 · Primary completion Oct 23, 2021
Drug: ALLO-647; Fludarabine and 1 more · For: Relapsed/Refractory Large B Cell Lymphoma; Relapsed/Refractory Follicular Lymphoma
Sites: Gilbert, Arizona; Stanford, California; Denver, Colorado · 7 sites in all
Allogene TherapeuticsIndustry
NCT05000450 · 6 participants · Start Jun 6, 2021 · Primary completion Oct 11, 2023
Drug: ALLO-647; Fludarabine and 1 more · For: Relapsed/Refractory Multiple Myeloma
Sites: Denver, Colorado; Austin, Texas; Houston, Texas · 4 sites in all
Allogene TherapeuticsIndustry
NCT05714345 · 2 participants · Start Nov 1, 2023 · Primary completion Feb 20, 2024
Drug: ALLO-647; Fludarabine and 1 more · For: Relapsed/Refractory Large B Cell Lymphoma
Sites: Louisville, Kentucky; Brussels, Belgium
Newest research
PubMed records naming it or its code names, newest first.
- Allogeneic CD70-Targeted Chimeric Antigen Receptor T-Cell Therapy for Advanced Renal Cell Carcinoma: Results From the Phase I TRAVERSE Trial.
Srour SA, Chahoud J, Drakaki A, et al. · J Clin Oncol 2026
- Allogeneic Chimeric Antigen Receptor T-Cell Products Cemacabtagene Ansegedleucel/ALLO-501 in Relapsed/Refractory Large B-Cell Lymphoma: Phase I Experience From the ALPHA2/ALPHA Clinical Studies.
Locke FL, Munoz JL, Tees MT, et al. · J Clin Oncol 2025
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.